- Home
- LPTX vs BCV Comparison
LPTX vs BCV Comparison
Compare LPTX & BCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- BCV
- Stock Information
- Founded
- LPTX 2011
- BCV 1971
- Country
- LPTX United States
- BCV United States
- Employees
- LPTX N/A
- BCV N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- BCV Finance/Investors Services
- Sector
- LPTX Health Care
- BCV Finance
- Exchange
- LPTX Nasdaq
- BCV Nasdaq
- Market Cap
- LPTX 119.6M
- BCV 110.8M
- IPO Year
- LPTX N/A
- BCV N/A
- Fundamental
- Price
- LPTX $0.33
- BCV $19.21
- Analyst Decision
- LPTX Hold
- BCV
- Analyst Count
- LPTX 1
- BCV 0
- Target Price
- LPTX N/A
- BCV N/A
- AVG Volume (30 Days)
- LPTX 3.3M
- BCV 26.3K
- Earning Date
- LPTX 08-11-2025
- BCV 01-01-0001
- Dividend Yield
- LPTX N/A
- BCV 8.13%
- EPS Growth
- LPTX N/A
- BCV N/A
- EPS
- LPTX N/A
- BCV N/A
- Revenue
- LPTX N/A
- BCV N/A
- Revenue This Year
- LPTX N/A
- BCV N/A
- Revenue Next Year
- LPTX N/A
- BCV N/A
- P/E Ratio
- LPTX N/A
- BCV N/A
- Revenue Growth
- LPTX N/A
- BCV N/A
- 52 Week Low
- LPTX $0.22
- BCV $14.09
- 52 Week High
- LPTX $4.79
- BCV $18.11
- Technical
- Relative Strength Index (RSI)
- LPTX 48.69
- BCV 69.55
- Support Level
- LPTX $0.28
- BCV $18.90
- Resistance Level
- LPTX $0.36
- BCV $19.14
- Average True Range (ATR)
- LPTX 0.04
- BCV 0.19
- MACD
- LPTX 0.01
- BCV 0.01
- Stochastic Oscillator
- LPTX 39.43
- BCV 98.89
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.